Corvus Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies. Co.'s product pipeline are: CPI-006, B-Cell Activating anti-CD73 antibody, which is an investigational, humanized, engineered anti CD73 monoclonal antibody that is designed to activate various immune cells including B cells, which are the cells responsible for antibody production; CPI-818, ITK Inhibitor, which is an investigational selective, orally bioavailable, covalent inhibitor of ITK designed to have low nanomolar affinity; and Ciforadenant, which is an oral, small molecule antagonist of the A2A receptor for adenosine. The CRVS stock yearly return is shown above.
The yearly return on the CRVS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CRVS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|